Sage Therapeutics said on Monday that its board has unanimously rejected Biogen’s $469 million offer, stating it ...

This was the stock's fifth consecutive day of gains.

Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...

Sage’s board of directors said Biogen’s offer “undervalues” the company, but will explore other strategic alternatives to ...

The company said Biogen's offer to buy all outstanding shares of Sage that it does not already own for $7.22 apiece, ...

The U.S. Food and Drug Administration has approved monthly maintenance dosing for Japan's Eisai and partner Biogen's ...

Sage Therapeutics rejected a takeover offer from Biogen ( BIIB) and said it started a process to review its strategic ...

Chris Viehbacher spoke out about the uncertain policy environment for life sciences companies, though he didn't single ...

Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...

The monthly maintenance regimen, which offers a more convenient frequency than the initially approved treatment schedule for ...